(Richmond Hill, Ontario) – Helix BioPharma Corp. (TSX: “HBP”) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced it has closed a private placement financing of 2,940,000 units of the Company (“Units”) and the disposition of shares of the Company’s Polish subsidiary, Helix Immuno-Oncology S.A. (“HIO”), representing an 8.5% stake in HIO (together with the Units, the “Purchased Securities”) for aggregate gross proceeds of approximately CAD $3,000,000, or $1.02 per Purchased Security.
- 0 Comments
- Corporate presentation